Clinical trial Recruiting at 1 site Observational Ages 20 to 80

See if serum BDNF levels relate to outcomes in chronic low back pain

Official title: The Prediction of Clinical Outcome Using the Serum BDNF Level

Run by Keimyung University Dongsan Medical Center · NCT07776379 · Data updated 2026-11-12

This study tests whether blood BDNF levels can help predict how patients with chronic low back pain will do over time.

More Chronic Low-back Pain trials

Quick facts

Study typeObservational
Ages20 Years to 80 Years
SexAll
Enrollment70 (estimated)
SponsorKeimyung University Dongsan Medical Center
Academic / other
Locations1 site (Daegu, Daegu)
StatusRecruiting
StartedAugust 13, 2026
Main results expectedMarch 30, 2028
Study endsMay 30, 2028
Registry record updatedAugust 21, 2026
Trial IDNCT07776379 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with chronic low back pain due to disc degeneration or spinal stenosis, with MRI evidence, and no excluded comorbidities, may be eligible.

Probably not a fit

Patients with secondary back pain, recent spine surgery, inflammatory or neuromuscular conditions, or medications affecting BDNF may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study explores whether serum Brain-Derived Neurotrophic Factor (BDNF) levels are linked to clinical outcomes in adults with chronic low back pain due to disc degeneration or spinal stenosis. Blood samples will be collected for ELISA analysis alongside standard assessments, and participants may receive an erector spinae plane block as part of the protocol. The study relies on MRI-confirmed disc pathology and excludes patients with conditions or medications known to affect BDNF. By correlating BDNF with pain, function, and other outcomes, the trial aims to identify potential markers for prognosis or stratification. The investigation is conducted at Keimyung University Dongsan Medical Center in Daegu, Korea.

Why it matters

Potential benefit: If correlations are found, BDNF could become a biomarker to help predict who might respond best to certain treatments.

How similar studies have gone: Some prior work has explored BDNF as a biomarker in musculoskeletal pain, but this study addresses a relatively novel link in chronic low back pain.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Chronic low back pain patients with or without leg pain due to disc degeneration or spinal stenosis
* Patients who have MRI

Exclusion Criteria:

* Secondary low back pain (spine fracture, infection, tumor)
* recent history of spine surgery
* systemic inflammatory disease (rheumatoid arthritis, SLE, ankylosing spondylitis)
* peripheral neuropathy or central nervous system injury
* fibromyalgia
* drugs which can affect the serum BDNF level (anti depressant, anti parkinsonian drug, acetylcholinesterase inhibitor, anti psychotics)

Where it's running

  • Ji Hee
    Daegu, Daegu, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.